News

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to treat gout, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track

Audax Private Equity (“Audax”) announced today it has entered into a definitive agreement to acquire the Clinical Services business of Avantor, Inc.

Fapon Biotech is a global leader in the In-vitro Diagnostics (IVD) industry, with a steadfast commitment to advancing global health by providing innovative diagnostic solutions. As the World Health Organization (WHO) declared monkeypox outbreak as a public health

Phanes Therapeutics, Inc. a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PT217 for the treatment of neuroendocrine carcinoma (NEC).

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR)

Monopar Therapeutics Inc., a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the successful dosing of the first patient in its open-label Phase

Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to VLX-1005, a small molecule 12-LOX

Concept Matrix Solutions, Inc. or the a privately held vertically integrated biotechnology company dedicated to developing and manufacturing innovative delivery forms in both pharmaceutical and nutraceutical spaces today announced that it has received patent

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for treatment of life-threatening pulmonary diseases, today announced